Skip to content
Teethgrinder – Lifestyle
Author:
Diakonos Oncology
Diakonos Oncology Shares Updated DOC1021 GBM Survival Data and Unveils Melanoma Clinical Study at ASCO 2026
June 5, 2026
Diakonos Oncology Awarded Fast Track Designation by FDA for DOC1021 (dubodencel) in Unresectable or Metastatic Cutaneous Melanoma
May 7, 2026
Diakonos Oncology Reports Positive Clinical Data from Phase 1 Pancreatic Cancer Study and Expanded Access Program in Glioblastoma at AACR and AAN 2026
May 3, 2026
/C O R R E C T I O N — Diakonos Oncology/
April 1, 2026
Diakonos Oncology to Showcase DOC1021 (dubodencel) Clinical Data in Pancreatic Cancer and Glioblastoma at AACR and ANN 2026
March 18, 2026